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Abstract
Background: Statins are extensively used for cardiovascular disease prevention. Statins reduce mortality rates more
than other lipid-modulating drugs, although evidence from randomized controlled trials also suggests that statins
unexpectedly increase the risk of diabetes and improve immune function. Physiologically, statins would be
expected to lower androgens because statins inhibit production of the substrate for the local synthesis of
androgens and statins’ pleiotropic effects are somewhat similar to the physiological effects of lowering
testosterone, so we hypothesized that statins lower testosterone.
Methods: A meta-analysis of placebo-controlled randomized trials of statins to test the a priori hypothesis that
statins lower testosterone. We searched the PubMed, Medline and ISI Web of Science databases until the end of
2011, using ‘(Testosterone OR androgen) AND (CS-514 OR statin OR simvastatin OR atorvastatin OR fluvastatin OR
lovastatin OR rosuvastatin OR pravastatin)’ restricted to randomized controlled trials in English, supplemented by a
bibliographic search. We included studies with durations of 2+ weeks reporting changes in testosterone. Two
reviewers independently searched, selected and assessed study quality. Two statisticians independently abstracted
and analyzed data, using random or fixed effects models, as appropriate, with inverse variance weighting.
Results: Of the 29 studies identified 11 were eligible. In 5 homogenous trials of 501 men, mainly middle aged with
hypercholesterolemia, statins lowered testosterone by -0.66 nmol/l (95% confidence interval (CI) -0.14 to -1.18). In 6
heterogeneous trials of 368 young women with polycystic ovary syndrome, statins lowered testosterone by -0.40
nmol/l (95% CI -0.05 to -0.75). Overall statins lowered testosterone by -0.44 nmol/l (95% CI -0.75 to -0.13).
Conclusions: Statins may partially operate by lowering testosterone. Whether this is a detrimental side effect or
mode of action warrants investigation given the potential implications for drug development and prevention of
non-communicable chronic diseases.
See commentary article here http://www.biomedcentral.com/1741-7015/11/58
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Background
Statins are extensively used in the West for secondary
prevention of cardiovascular diseases, and have contrib-
uted to a reduction in cardiovascular disease mortality
rates. Statin use will become more common globally
with the emerging epidemic of cardiovascular disease in
developing countries and the increasing availability of
statins off patent. Randomized controlled trials (RCTs)
show statins reduce mortality rates more than other
commonly used lipid-modulating therapies [1,2], such as
niacin, fibrates and ezetimibe (where the evidence is
limited), and are beneficial for some cardiovascular dis-
eases poorly correlated with cholesterol [3], although
statins increase the risk of diabetes [4], with a dose-
dependent effect [5]. In RCTs statins also reduce inflam-
mation [6,7] and improve immune function [8,9]. Cur-
rently, there is no known, coherent explanation for this
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specific pattern of pleiotropic effects, and no identified
‘active ingredient’, despite relevance to drug discovery,
existing therapies and modifiable risk factors.
Statins inhibit the enzyme 3-hydroxy-3-methyl-glutaryl-
CoA (HMG-CoA) reductase, which reduces cholesterol
production. In contrast niacin blocks the breakdown of
fats, fibrates activate peroxisome proliferator-activated
receptor (PPAR)-a and ezetimibe inhibits cholesterol
absorption. All modulate circulating lipids, but only statins
also inhibit de novo synthesis of cholesterol throughout
the body [10]. Concern has always existed that statins
might impair testosterone production [11] either by redu-
cing availability of its preferred substrate, that is, locally
produced de novo cholesterol in the gonads [12] and else-
where, or by inhibiting steps in the steroidogenesis process
[13], but this concern has been considered of little clinical
significance [14-16]. Lowering androgens potentially
explains some of statins’ effects. An RCT among men
found testosterone therapy enhanced glucose metabolism
[17], whilst impaired glucose metabolism may be a side
effect of androgen deprivation therapy [18]. Men with
naturally low androgens due to Klinefelter’s syndrome are
more prone to diabetes [19]. Extensive experimental evi-
dence indicates that testosterone is immunomodulatory
[20,21] and impairs immune response [22,23]. Given sta-
tins’ physiological mechanism would be expected to
reduce androgens as well as the similarity between the
effects of statins and of reducing androgens, we hypothe-
sized a priori that the pleiotropic effects of statins could
be due to lowering of androgens, that is, that statins lower
androgens and that lower androgens might mediate the
pleiotropic effects of statins. Here, we carried out a meta-
analysis of placebo-controlled randomized trials, to avoid
bias by indication, in men and women to examine whether
statins reduced total testosterone.
Methods
We implemented this meta-analysis following the Pre-
ferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) checklist (Additional file 1). Two
reviewers (CMS and SLAY) independently searched for
and selected studies, resolving differences by consensus.
Two statisticians (GF and BJC) extracted information
from the selected studies.
Data sources and searches
We systematically searched the PubMed, Medline and ISI
Web of Science databases until the end of 2011 using
search term ‘(Testosterone OR androgen) AND (CS-514
OR statin OR simvastatin OR atorvastatin OR fluvastatin
OR lovastatin OR rosuvastatin OR pravastatin)’ with the
search limited to RCTs of studies in humans in English,
because an initial search suggested the relevant literature
was in English. From our search, we discarded any
studies that were not relevant from the title or abstract
and read the remaining to identify placebo-controlled
randomized trials of statins with testosterone reported.
We also used the references of the selected trials to iden-
tify additional relevant trials.
Study selection
We included any published placebo-controlled rando-
mized trial in English of at least 2 weeks’ duration examin-
ing the effect of statins on testosterone in adults, because
statins act rapidly on cholesterol [11]. We did not consider
trials in children, because children have different levels of
testosterone, and statins are rarely used in children. We
did not otherwise select by participant characteristics,
because statins are used for the same purpose in a wide
variety of patients, and there is no reason to think that sta-
tins have different effects by patient subgroup.
Data extraction and quality assessment
A statistician (GF) extracted information by trial arm on
number of participants, testosterone assays used, and
mean and standard deviation of the change in testoster-
one during the trial. Where this information was not pro-
vided in full, the statistician (GF) made conservative
estimates based on the information available. A second
statistician (BJC) then checked the information extracted
and any estimates. The reviewers (CMS and SLAY) inde-
pendently used an established tool to evaluate the quality
of each trial [24], and a sensitivity analysis was done
excluding the lower quality trials.
Data synthesis and analysis
We used funnel plots to assess publication bias, and I2 to
assess heterogeneity between trials. To obtain an estimate
of the difference in mean testosterone between statin and
placebo groups, we combined the results of the selected
trials using inverse variance weighting and a fixed or ran-
dom effects model depending on the level of heterogene-
ity, using the ‘metacont’ function from the ‘meta’ package
of R 2.14.1 (R Development Core Team, Vienna, Austria).
We considered men and women together and separately
because of the different hormone milieu by sex. We did
no other subgroup analysis.
This study is an analysis of published data, which does
not require ethics committee approval.
Results
The initial searches yielded 27 studies. Two additional
trials [11,25] were found from the bibliographic search.
We discarded 18 studies. Three were clearly not relevant
based on title, four had no control group, three had the
control group taking other drugs (namely neomycin, cho-
lestyramine or other lipid-lowering drugs and atorvasta-
tin plus ezetimibe), four were not randomized controlled
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trials of statins, two were largely duplicates of other
included publications [26,27] and two provided insuffi-
cient information. Details of these 18 excluded studies
are given in Additional file 2. Of the 11 trials remaining,
1 small trial of 15 men and 7 women providing only
graphs had an implausibly high post-intervention value
of testosterone for women in the placebo group (mean
approximately 5.2 nmol/l for 3 women, no standard
deviation given) [28], so these 7 women were also
excluded. Figure 1 shows the search strategy resulting in
these 11 placebo-controlled randomized trials.
Table 1 shows there were 5 trials over 25 years of 501
men, mainly middle aged with hypercholesterolemia, tak-
ing typical doses of statins. There were 6 recent trials of
368 young women with polycystic ovary syndrome. Most
of the trials were in western settings and were carried out
by teams affiliated with or funded by pharmaceutical
companies. Most of the trials were of average quality as
shown in Additional file 3, with the larger, more recent
ones generally of higher quality.
Funnel plots gave little indication of publication bias
among men (Figure 2), but among women, the trials were
more diverse. For completeness Figure 2 also shows the
funnel plot for men and women together.
Figure 3 (top panel) shows a forest plot for men. The
trials were homogeneous (I2 = 0%), with the overall esti-
mate within the confidence intervals of all trials. Statins
lowered testosterone by about 3.4% among men (-0.66
nmol/l, 95% confidence interval (CI) -0.14 to -1.18) in
both fixed and random effects models, and the estimate
was similar (-0.73 nmol/l, 95% CI -0.20 to -1.26) includ-
ing only the higher quality trials [15,16,29]. Figure 3
(middle panel) shows a forest plot for women. The trials
were heterogeneous (I2 = 90.1%). Statins lowered testos-
terone by about 12.3% among women (-0.40 nmol/l, 95%
CI -0.05 to -0.75) in a random effects model, with similar
results when the most extreme study [30] was omitted.
The estimate for women was also similar, but included
no effect (-0.50 nmol/l, 95% CI 0.06 to -1.06) when con-
sidering only the higher quality trials [30-33]. For com-
pleteness, Figure 3 (bottom panel) shows a forest plot for
men and women together. The trials were heterogeneous
(I2 = 79%). Statins lowered testosterone overall (-0.44
nmol/l, 95% CI -0.13 to -0.75) in a random effects model;
results were similar when each of the three most influen-
tial trials was removed, or when only considering the
higher quality trials (-0.57 nmol/l, 95% CI -0.12 to -1.02)
[15,16,29-33].
Discussion
This meta-analysis of placebo-controlled randomized
trials suggests statins reduce testosterone. Among men
the evidence was homogeneous and largely related to
typical doses for the target group using statins for the
prevention of cardiovascular disease, where statins
potentially lowering testosterone has always been a con-
cern [11,12,14-16]. Among women less concern has
existed [34]. Very few trials have examined testosterone
among women using statins for the prevention of cardi-
ovascular disease, and our findings were less robust for
women than men. Nevertheless, statins have recently
been discovered as an effective anti-androgen treatment
for polycystic ovary syndrome [25,35]. A recent meta-
analysis of statin therapy for women with polycystic
ovary syndrome concluded that statins reduced testos-
terone based on the same literature [36].
To the best of our knowledge no previous meta-analy-
sis of placebo-controlled randomized trials has assessed
the effect of statins on testosterone among men. Two
trials comparing simvastatin 80 mg/day with 40 mg/day
among in total 640 men found median testosterone
lower by 10.3% and 7.5% respectively after 48 weeks
[34], consistent with the 3.4% reduction here among
Figure 1 Selection process for the placebo-controlled
randomized trials of the effects of statins on testosterone.
Schooling et al. BMC Medicine 2013, 11:57
http://www.biomedcentral.com/1741-7015/11/57
Page 3 of 9
Table 1 Characteristics of placebo-controlled randomized trials giving the effects of statins on testosterone
Lead author/
publicationyear/
reference
Study Participants Authors: funding and
affiliations
Setting Duration Statin and daily
dose
Testosterone assessment
method
Comments Men Women Mean
age,
years
Health status
Statin/
placebo (no.
completed
study)
Tobert 1982 [11] Europe 4 weeks Lovastatin, multiple
doses
Various radio immunoassays 47/
10a
0 29 Healthy volunteers Affiliations include MSD
Dobs 2000 [16] US 24 weeks Simvastatin 20/40
mg/pravastatin 40
mg
Radio immunoassay 85/
28
0 40 Hypercholesterolemia Affiliations include Merck
Dobs 2000 [15] US 12 weeks Simvastatin 80 mg Radio immunoassay 37/
39
0 45 High LDL cholesterol Affiliations include Merck
Hyyppä 2003 [29] Finland 12 weeks Simvastatin 20 mg Direct competitive
immunoassay
120/
120
0 48 Hypercholesterolemia None given
Boehm 2004 [28] Germany 3
months
Pravastatin 40 mg Competitive
electrochemiluminescence
immunoassay
6/9 4/3b 65 Hypercholesterolemia None given
Banaszewska 2007
[26]
Poland 12 weeks Simvastatin 20 mg Specific chemiluminescence
assay
Also using
OCPs
0 45/48 24 PCOS NIH and drug donations
Banaszewska 2009
[27]
Poland 3
months
Simvastatin 20 mg Specific
electrochemiluminescence
assay
Also using
metformin
0 37/36 25 PCOS NIH and Polish State
Committee for Scientific
Research
Sathyapalan 2009 [30] UK 12 weeks Atorvastatin 20 mg Chemiluminescent
immunoassay
0 19/18 28 PCOS Pfizer
Kazerooni 2010 [32] Iran 12 weeks Simvastatin 20 mg Radio immunoassay Also using
metformin
0 42/42 25 PCOS None
Raja-Khan 2011 [31] US 6 weeks Atorvastatin 40 mg Not given 0 9/11c 33 PCOS NIH, Penn State Univeristy,
Pfizer
Rashidi 2011 [33] Iran 8 weeks Simvastatin 20 mg Chemiluminescence assay Also receiving
IVF treatment
0 32/29 25 PCOS Daru Darman Pars Co.
aSubjects with missing data excluded, but number excluded not clearly given; at least two from the statin arm were excluded.
bData not used because of an implausible value for testosterone at study end in the placebo group.
cTwo subjects with missing data excluded, but not clear from which arm(s).
IVF = in vitro fertilization; MSD = Merck, Sharp and Dohme; NIH = National Institute of Health; OCP = oral contraceptives; PCOS = polycystic ovary syndrome.
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men mainly using simvastatin 20 mg/day, suggesting a
possible dose response of statins on testosterone.
The clinical significance of this reduction in testoster-
one with statins is difficult to gauge. The normal range of
testosterone is wide [37] and sexual function similar
across the range [38]. Erectile dysfunction is a rare side
effect of statins [39], perhaps because statins’ have benefi-
cial effects on cardiovascular function that would coun-
teract changes of this magnitude in testosterone.
However, large changes in testosterone (and libido) can
occasionally occur with statin use [40], which are reversi-
ble by statin withdrawal [40]. The impact on population
health may be more germane, where statins causing dia-
betes could be another side effect. We are not aware of
any study examining whether lowering testosterone med-
iates the effect of statins on diabetes, as this possibility
has not, to the best of our knowledge, been considered
before, and remains speculative. Moreover, observational
studies suggest serum testosterone has sex-specific phy-
siological effects on diabetes, negative among men [41],
but positive among women [41], when statins increase
diabetes in both sexes [4,5,42]. We could not identify any
RCT confirming testosterone therapy increases diabetes
incidence among women. In postmenopausal women,
RCTs of testosterone therapy indicate little effect on glu-
cose metabolism [43]. In younger women, some RCTs
indicate that low doses of testosterone may improve glu-
cose metabolism [44,45]; female to male transsexuals
given high doses of testosterone have improved glucose
metabolism [46]. Nevertheless, distinct effects of testos-
terone on diabetes may occur by dose, sex and age with
the reduction in testosterone with statin treatment insuf-
ficient to modulate diabetes risk consistently. This meta-
analysis also raises the question as to whether lowering
testosterone is a side effect of statin therapy or contri-
butes to statins’ mode of action, which could inform new
treatments and prevention policies. Observationally tes-
tosterone is inversely associated with cardiovascular mor-
tality [47]; whether testosterone is causal or a marker of
health is unknown [47]. No RCT has shown testosterone
therapy reduces cardiovascular events; two RCTs of tes-
tosterone therapy were halted because of adverse, mainly
cardiovascular events, among men allocated to testoster-
one [48,49]. Natural experiments suggest lower testoster-
one protects against specifically ischemic heart disease
mortality, with a relatively lower risk in men legally
castrated [50] or with Klinefelter’s syndrome [51]. Physio-
logically lowering testosterone may reduce thromboxane
and platelet activation [52], specifically relevant to redu-
cing ischemic cardiovascular disease but not to diabetes.
However, whether lowering testosterone with statin
treatment modulates cardiovascular disease, via these or
other pathways, has not been examined.
Despite providing a meta-analysis of all known placebo-
controlled randomized trials, limitations exist. First, given
when they were conducted, not all the trials had high
quality scores. However, they had the expected effects on
lipids. Second, not all the trials were intended to assess the
effects of statins on testosterone. However, the trial, largely
designed for this purpose [29], is influential, and alone
found statins reduced testosterone [29]. Third, testoster-
one was not assayed in the same way in all trials (Table 1).
Testosterone is difficult to measure, particularly among
women. Heterogeneity for women could be due to differ-
ing, possibly suboptimal, testosterone assay techniques, for
which we compensated by using a random effects model.
Imprecision in the assays also reduces power but would
not bias a comparison between statin and placebo groups
unless statins interfered with the testosterone assay. Ster-
oids can cause assay interference. We could find no evi-
dence that statins cause assay interference. Fourth, too few
trials existed to assess dose-response effects or compare
???? ?????? ????
? ? ?
Figure 2 Funnel plots of placebo-controlled randomized trials examining the effects of statins on testosterone by sex and for men
and women together.
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Figure 3 Forest plots of placebo-controlled randomized trials examining the pooled effects of statins on testosterone for men (top
panel), women (middle panel) and both sexes (bottom panel). In Kazerooni et al. [32], the reported SD was much smaller than in other
trials, whereas the reported SD multiplied by the square root of the sample size was similar to the SDs reported in other trials. If we were to
assume that the reported SD was actually the standard error, the pooled estimate for women would be -0.40 nmol/l (95% CI -0.83 to 0.03) and
the overall pooled estimate would be -0.44 nmol/l (95% CI -0.80 to -0.08). Mean = mean difference; SD = standard deviation.
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hydrophilic (fluvastatin, rosuvastatin, and pravastatin) to
lipophilic (atorvastatin, lovastatin, and simvastatin) statins.
However, atorvastatin, pravastatin or simvastatin do not
differ substantially in their effects on cardiovascular disease
[53]. Fifth, other RCTs may have assessed but not reported
the effects of statins on testosterone. Given, the concern
that statins lower testosterone [11,12,14-16], these might
perhaps be trials where statins reduced testosterone among
men. Sixth, RCTs are not always tagged as such and could
be missed. To check we searched using ‘trial’ as a search
term instead of restricting the search to RCTs, which gave
the same selection (data not shown). Seventh, evidence
concerning the effect of statins on testosterone in post-
menopausal women is lacking. Eighth, considering the
effects of statins on testosterone for men and women
together may be invalid, hence results stratified and pooled
by sex. Ninth, the effect of statins on testosterone in differ-
ent ethnic groups is lacking. Effects might differ in settings,
such as China, where peak testosterone [37,54], androgen
related parameters [55,56] and ischemic heart diseases
mortality rates [57] are all lower than in western popula-
tions. Finally, cross-sectional studies were not included,
because these provide evidence from which it is difficult to
assess causality. The larger cross sectional studies only con-
sidered men and generally observed lower testosterone
among statin users than non-users [58-60].
Conclusions
This meta-analysis shows that statins reduce testosterone.
This finding does not demonstrate that androgens mediate
any health effect of statins, but raises the question as to
whether testosterone modulation plays a role in statins’
effects on health, particularly among men where testoster-
one is an important hormone. Whether reducing testos-
terone enhances or impairs the protective effects of statins
on cardiovascular mortality needs to be determined
urgently, because it could enable the development of
enhanced statin based treatments, the development of
other drugs in the same class and the identification of
potentially modifiable population-wide risk factors for sev-
eral non-communicable chronic diseases.
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